Experimental Chemotherapy

Update : 2016-12-01


Although cancer treatments have gradually improved during past decades, we are still facing problems to surmount in prevention and therapy of cancers. Recent advances in molecular-based understanding of cell proliferation have provided the rationale for the molecular-targeted therapy to control cancer. The aim of this research division is to identify possible targets, to clarify the function of molecular targets, and ultimately to develop an effective molecular-targeted therapy of cancer. For this purpose, we are investigating the molecular mechanisms of anti-cancer drug resistance, apoptosis resistance, and tumor metastasis. In addition, we are investigating the nature of cancer stem cells.


  1. Aggrus: a platelet aggregation-inducing factor that is associated with hematogenous metastasis
  2. Resistance mechanisms to molecular targeted therapy, and therapeutic strategies to overcome the resistance
  3. Targeting cancer stem cells and their regulation
  4. Molecular mechanisms of survival signaling pathways



Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Gainor, J.F., Motoi, N., Dobashi, A., Tambo, Y., Kitazono, S., Sato, S., Koike, S., lafrate, A.J., Mino-Kenudson, M., Ishikawa, Y., Shaw, A.T., Engelman, J.A., Takeuchi, K., Nishio, M., Fujita, N.
P-glycoprotein mediates ceritinib resistance in ALK-rearranged non-small-cell lung cancer. EBioMedicine, 3: 54-66, 2016.
Sekiguchi, T., Takemoto, A., Takagi, S, Takatori, K., Sato, S., Takami, M., Fujita, N.
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7: 3934-3946, 2016.
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E.L., Koike, S., Shaw, A.T., Engelman, J.A., Fujita, N.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer.
Clin. Cancer Res., 21. 166-174, 2015.
Katayama, R., Friboulet, L., Koike, S., Lockerman, E.L., Khan, T.M., Gainor, J.F., Iafrate, A.J., Takeuchi, K., Taiji, M., Okuno, Y., Fujita, N., Engelman, J.A., Shaw, A.T.
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Clin. Cancer Res., 20, 5686-5696 (2014)
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-Hara, T., Song, Y., Engelman, J.A., Fujita, N.
Cytotoxic activity of Tivanitib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73, 3087-3096 (2013)


Naoya FujitaiDirector and Chiefj
3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
TelF81-3-3570-0481 FaxF81-3-3570-0484

Return to Top of Page